All In Biotech

Drug Trial Radar · NCT01732770

Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis

A Randomized Double-blind Study to Evaluate the Safety and Efficacy of Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates

Last checked: Nov 20, 2026Latest source record: Mar 10, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 643 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

643

Actual

Start

Nov 7, 2012

Primary completion

Jan 7, 2015

Study completion Jan 7, 2015

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Nov 26, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Female only, from 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will compare the effectiveness of denosumab treatment every 6 months with once yearly zoledronic acid treatment on bone mineral density (BMD) at various skeletal sites.

Conditions

  • Post Menopausal Osteoporosis

Interventions

  • DenosumabBiological

    Denosumab 60 mg administered by subcutaneous injection once every 6 months.

  • Zoledronic AcidDrug

    Zoledronic acid 5 mg administered by intravenous infusion once a year

  • Placebo to DenosumabDrug

    Administered by subcutaneous injection once every 6 months

  • Placebo to Zoledronic AcidDrug

    Administered by intravenous infusion once a year

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 12 - Non-inferiority AnalysisTime frame: Baseline and Month 12

Locations

45 sites in 7 countries. Site status is shown where the registry gives one.

  • Research Site

    Santa Monica, California

  • Research Site

    Lakewood, Colorado

  • Research Site

    Longmont, Colorado

  • Research Site

    Washington D.C., District of Columbia

  • Research Site

    Bethesda, Maryland

  • Research Site

    Hagerstown, Maryland

  • Research Site

    Detroit, Michigan

  • Research Site

    West Haverstraw, New York

  • Research Site

    Houston, Texas

  • Research Site

    Maroubra, New South Wales, Australia

  • Research Site

    Penrith, New South Wales, Australia

  • Research Site

    St Leonards, New South Wales, Australia

  • Research Site

    Box Hill, Victoria, Australia

  • Research Site

    Geelong, Victoria, Australia

  • Research Site

    Parkville, Victoria, Australia

  • Research Site

    Brussels, Belgium

  • Research Site

    Brussels, Belgium

  • Research Site

    Brussels, Belgium

  • Research Site

    Brussels, Belgium

  • Research Site

    Genk, Belgium

  • Research Site

    Leuven, Belgium

  • Research Site

    Liège, Belgium

  • Research Site

    Merksem, Belgium

  • Research Site

    Tessenderlo, Belgium

  • Research Site

    Wilrijk, Belgium

  • Research Site

    Yvoir, Belgium

  • Research Site

    Calgary, Alberta, Canada

  • Research Site

    Vancouver, British Columbia, Canada

  • Research Site

    Halifax, Nova Scotia, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Québec, Quebec, Canada

  • Research Site

    Aalborg, Denmark

  • Research Site

    Ballerup Municipality, Denmark

  • Research Site

    Vejle, Denmark

  • Research Site

    Bialystok, Poland

  • Research Site

    Krakow, Poland

  • Research Site

    Torun, Poland

  • Research Site

    Warsaw, Poland

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.